marketcaparena
Search

    TKNO

    Alpha Teknova, Inc.

    Company overview

    Market capitalization
    $493.93M
    Employees
    158
    Latest publication
    2026-09-29
    About Alpha Teknova, Inc.

    Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20212021-03-31 · USDQ4 20202020-12-31 · USDQ3 20202020-09-30 · USDQ2 20202020-06-30 · USDQ1 20202020-03-31 · USD
    Total Revenue12,185,000USD9,078,000USD10,157,000USD8,984,000USD6,044,000USD6,112,000USD
    Cost Of Revenue7,300,000USD4,053,000USD4,588,000USD3,896,000USD2,575,000USD2,483,000USD
    Gross Profit4,885,000USD5,025,000USD5,569,000USD5,088,000USD3,469,000USD3,629,000USD
    Research Development554,000USD700,000USD482,000USD358,000USD341,000USD326,000USD
    Selling And Marketing Expenses2,122,000USD705,000USD840,000USD558,000USD481,000USD349,000USD
    General And Administrative Expenses4,812,000USD—————
    Other Operating Expenses287,000USD—————
    Total Operating Expenses7,775,000USD5,853,000USD4,774,000USD2,936,000USD2,765,000USD2,617,000USD
    Operating Income-2,890,000USD-828,000USD795,000USD2,152,000USD704,000USD1,012,000USD
    Total Other Income Expense Net-250,000USD8,000USD16,000USD17,000USD19,000USD11,000USD
    Net Interest Income-252,000USD7,000USD13,000USD19,000USD23,000USD—
    Income Before Tax-3,140,000USD-820,000USD811,000USD2,169,000USD723,000USD1,023,000USD
    Income Tax Expense30,000USD-165,000USD234,000USD636,000USD211,000USD75,000USD
    Net Income-3,170,000USD-655,000USD577,000USD1,533,000USD512,000USD948,000USD
    Selling General Administrative—4,161,000USD3,165,000USD1,733,000USD1,656,000USD1,655,000USD
    Interest Income—7,000USD————
    Tax Provision—-165,000USD234,000USD636,000USD211,000USD—
    Net Income From Continuing Ops—-655,000USD577,000USD1,533,000USD512,000USD—
    Ebit—-828,000USD795,000USD2,152,000USD704,000USD1,012,000USD
    Ebitda—-176,000USD1,366,000USD2,694,000USD1,182,000USD1,465,000USD
    Depreciation And Amortization—652,000USD571,000USD542,000USD478,000USD453,000USD
    Reconciled Depreciation—652,000USD571,000USD542,000USD478,000USD453,000USD
    Net Income Applicable To Common Shares—-655,000USD—262,000USD87,000USD161,000USD
    Interest Expense——13,000USD———
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20202020-12-31 · USD
    Total Revenue31,297,000USD
    Cost Of Revenue13,542,000USD
    Gross Profit17,755,000USD
    Research Development1,507,000USD
    Selling General Administrative8,208,000USD
    Selling And Marketing Expenses2,229,000USD
    Unclassified Operating Expenses1,148,000USD
    Total Operating Expenses13,092,000USD
    Operating Income4,663,000USD
    Interest Income87,000USD
    Interest Expense63,000USD
    Net Interest Income87,000USD
    Income Before Tax4,726,000USD
    Income Tax Expense1,156,000USD
    Tax Provision1,156,000USD
    Net Income3,570,000USD
    Net Income From Continuing Ops3,570,000USD
    Ebit4,663,000USD
    Ebitda6,707,000USD
    Depreciation And Amortization2,044,000USD
    Reconciled Depreciation2,044,000USD
    Total Other Income Expense Net63,000USD
    Net Income Applicable To Common Shares608,000USD
    SourceLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets95,878,000USD98,657,000USD103,584,000USD107,625,000USD110,487,000USD113,993,000USD118,769,000USD124,099,000USD
    Cash And Equivalents6,004,000USD———————
    Cash And Short Term Investments17,436,000USD4,306,000USD5,912,000USD3,204,000USD24,000,000USD26,273,000USD30,396,000USD31,691,000USD
    Short Term Investments11,432,000USD13,478,000USD15,426,000USD18,912,000USD20,724,000USD22,896,000USD26,688,000USD25,546,000USD
    Total Current Assets30,824,000USD31,674,000USD34,511,000USD36,563,000USD38,057,000USD39,733,000USD42,776,000USD45,930,000USD
    Other Current Assets1,069,000USD14,822,000USD16,927,000USD21,310,000USD1,307,000USD1,271,000USD1,267,000USD1,960,000USD
    Other Non Current Assets1,127,000USD———————
    Total Liabilities33,278,000USD———————
    Total Current Liabilities6,872,000USD6,896,000USD7,537,000USD6,936,000USD6,478,000USD7,045,000USD11,211,000USD9,719,000USD
    Other Current Liabilities3,476,000USD———————
    Total Stockholder Equity62,600,000USD64,924,000USD68,775,000USD72,650,000USD76,057,000USD78,605,000USD82,394,000USD87,268,000USD
    Total Equity Including Noncontrolling Interest62,600,000USD———————
    Net Receivables5,408,000USD5,672,000USD4,618,000USD5,135,000USD5,140,000USD5,616,000USD4,312,000USD4,605,000USD
    Inventory6,911,000USD6,874,000USD7,054,000USD6,914,000USD7,610,000USD6,573,000USD6,801,000USD7,674,000USD
    Property Plant Equipment Net52,558,000USD54,132,000USD55,845,000USD57,517,000USD58,565,000USD60,137,000USD61,520,000USD63,273,000USD
    Intangible Assets11,369,000USD11,656,000USD11,943,000USD12,230,000USD12,517,000USD12,804,000USD13,091,000USD13,378,000USD
    Accounts Payable1,438,000USD1,618,000USD1,378,000USD1,084,000USD1,204,000USD1,555,000USD825,000USD975,000USD
    Short Term Debt1,958,000USD1,915,000USD1,876,000USD1,886,000USD1,886,000USD1,850,000USD5,845,000USD4,371,000USD
    Common Stock1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Retained Earnings-143,515,000USD-140,345,000USD-135,790,000USD-131,032,000USD-126,746,000USD-123,176,000USD-118,531,000USD-112,812,000USD
    Total Liab—33,733,000USD34,809,000USD34,975,000USD34,430,000USD35,388,000USD36,375,000USD36,831,000USD
    Other Current Liab—3,363,000USD4,283,000USD3,966,000USD3,383,000USD3,626,000USD4,511,000USD4,339,000USD
    Capital Stock—1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD1,000USD
    Cash—4,306,000USD5,912,000USD3,204,000USD3,276,000USD3,377,000USD3,708,000USD6,145,000USD
    Net Debt—10,351,000USD9,234,000USD12,699,000USD25,694,000USD25,968,000USD26,464,000USD24,441,000USD
    Short Long Term Debt Total—14,657,000USD15,146,000USD15,903,000USD28,970,000USD29,345,000USD30,172,000USD30,586,000USD
    Long Term Debt—13,170,000USD13,123,000USD13,076,000USD13,032,000USD12,989,000USD9,443,000USD10,857,000USD
    Property Plant Equipment Gross—72,794,000USD73,217,000USD73,595,000USD73,339,000USD73,675,000USD73,764,000USD74,712,000USD
    Common Stock Shares Outstanding—53,606,278shares53,543,334shares53,516,986shares53,448,736shares53,421,533shares53,374,839shares44,520,132shares
    Non Current Assets Total—66,983,000USD69,073,000USD71,062,000USD72,430,000USD74,260,000USD75,993,000USD78,169,000USD
    Non Current Liabilities Total—26,837,000USD27,272,000USD28,039,000USD27,952,000USD28,343,000USD25,164,000USD27,112,000USD
    Non Currrent Assets Other—1,195,000USD1,285,000USD1,315,000USD1,348,000USD1,319,000USD1,382,000USD1,518,000USD
    Net Working Capital—24,778,000USD26,974,000USD29,627,000USD31,579,000USD32,688,000USD31,565,000USD36,211,000USD
    Unclassified Current Assets—-13,478,000USD-15,426,000USD-18,912,000USD————
    Unclassified Non Current Liabilities—13,667,000USD14,149,000USD14,963,000USD14,920,000USD15,354,000USD15,721,000USD16,255,000USD
    Unclassified Equity—205,267,000USD204,563,000USD203,680,000USD202,801,000USD201,779,000USD200,923,000USD200,078,000USD
    Current Deferred Revenue————5,000USD14,000USD30,000USD34,000USD
    Short Long Term Debt——————4,045,000USD2,528,000USD
    Unclassified Current Liabilities——————-4,045,000USD-2,528,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Total Assets103,584,000USD118,769,000USD128,587,000USD152,261,000USD166,511,000USD62,911,000USD58,510,000USD
    Intangible Assets11,943,000USD13,091,000USD14,239,000USD17,556,000USD18,704,000USD19,852,000USD20,999,000USD
    Other Current Assets16,927,000USD1,267,000USD1,634,000USD2,374,000USD2,438,000USD1,137,000USD188,000USD
    Total Liab34,809,000USD36,375,000USD38,551,000USD52,376,000USD23,308,000USD10,506,000USD45,600,000USD
    Total Stockholder Equity68,775,000USD82,394,000USD90,036,000USD99,885,000USD143,203,000USD52,405,000USD12,910,000USD
    Other Current Liab4,283,000USD4,511,000USD5,563,000USD6,005,000USD5,495,000USD2,327,000USD4,767,000USD
    Common Stock1,000USD1,000USD—————
    Capital Stock1,000USD1,000USD0USD0USD0USD0USD0USD
    Retained Earnings-135,790,000USD-118,531,000USD-91,786,000USD-55,006,000USD-7,538,000USD2,265,000USD-1,305,000USD
    Cash5,912,000USD3,708,000USD28,484,000USD42,236,000USD87,518,000USD3,315,000USD4,144,000USD
    Cash And Short Term Investments5,912,000USD30,396,000USD28,484,000USD42,236,000USD87,518,000USD5,126,000USD9,676,000USD
    Total Current Assets34,511,000USD42,776,000USD45,660,000USD61,140,000USD101,204,000USD16,414,000USD15,416,000USD
    Total Current Liabilities7,537,000USD11,211,000USD8,875,000USD10,875,000USD7,743,000USD3,962,000USD5,580,000USD
    Net Debt9,234,000USD26,464,000USD1,974,000USD74,000USD-75,648,000USD-3,315,000USD-4,099,000USD
    Short Term Debt1,876,000USD5,845,000USD1,803,000USD2,223,000USD200,000USD—45,000USD
    Short Long Term Debt Total15,146,000USD30,172,000USD30,458,000USD42,310,000USD12,070,000USD—45,000USD
    Long Term Debt13,123,000USD9,443,000USD13,251,000USD21,976,000USD11,870,000USD——
    Short Term Investments15,426,000USD26,688,000USD0USD—0USD1,811,000USD5,532,000USD
    Net Receivables4,618,000USD4,312,000USD3,948,000USD4,283,000USD5,854,000USD6,569,000USD2,986,000USD
    Inventory7,054,000USD6,801,000USD11,594,000USD12,247,000USD5,394,000USD3,582,000USD2,566,000USD
    Accounts Payable1,378,000USD825,000USD1,493,000USD2,449,000USD2,248,000USD1,635,000USD768,000USD
    Property Plant Equipment Net55,845,000USD61,520,000USD66,836,000USD71,313,000USD29,810,000USD10,008,000USD5,450,000USD
    Property Plant Equipment Gross73,217,000USD73,764,000USD74,364,000USD71,313,000USD32,283,000USD10,008,000USD5,450,000USD
    Common Stock Shares Outstanding53,483,075shares46,745,905shares31,820,000shares28,084,000shares28,012,017shares3,976,628shares3,636,724shares
    Non Current Assets Total69,073,000USD75,993,000USD82,927,000USD91,121,000USD65,307,000USD46,497,000USD43,094,000USD
    Non Current Liabilities Total27,272,000USD25,164,000USD29,676,000USD41,501,000USD15,565,000USD6,544,000USD40,020,000USD
    Non Currrent Assets Other1,285,000USD1,382,000USD1,852,000USD2,252,000USD180,000USD24,000USD32,000USD
    Net Working Capital26,974,000USD31,565,000USD36,785,000USD50,265,000USD93,461,000USD12,452,000USD9,836,000USD
    Unclassified Current Assets-15,426,000USD——————
    Unclassified Non Current Liabilities14,149,000USD15,721,000USD16,425,000USD18,111,000USD-3,695,000USD—35,638,000USD
    Unclassified Equity204,563,000USD200,923,000USD181,822,000USD154,891,000USD150,741,000USD50,133,000USD14,195,000USD
    Current Deferred Revenue—30,000USD16,000USD198,000USD200,000USD——
    Short Long Term Debt—4,045,000USD————45,000USD
    Unclassified Current Liabilities—-4,045,000USD—————
    Other Liab———1,414,000USD3,695,000USD6,544,000USD4,382,000USD
    Good Will———0USD16,613,000USD16,613,000USD16,613,000USD
    Accumulated Other Comprehensive Income———0USD0USD7,000USD20,000USD
    Deferred Long Term Liab————3,422,000USD——
    Other Assets————180,000USD24,000USD32,000USD
    Non Current Liabilities Other————273,000USD——
    Net Tangible Assets————107,886,000USD-19,698,000USD-24,702,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-4,555,000USD-4,758,000USD-4,286,000USD-3,570,000USD-4,645,000USD-5,719,000USD-7,565,000USD-5,364,000USD
    Depreciation1,576,000USD1,581,000USD1,591,000USD1,590,000USD1,580,000USD1,645,000USD1,671,000USD1,626,000USD
    Stock Based Compensation695,000USD777,000USD850,000USD950,000USD852,000USD766,000USD760,000USD833,000USD
    Other Non Cash Items368,000USD558,000USD1,564,000USD522,000USD-125,000USD417,000USD3,375,000USD1,995,000USD
    Change To Account Receivables-1,061,000USD520,000USD-17,000USD472,000USD-1,349,000USD224,000USD-13,000USD-86,000USD
    Change To Inventory-233,000USD-598,000USD-36,000USD-1,525,000USD-209,000USD559,000USD3,339,000USD-767,000USD
    Change In Working Capital-1,489,000USD1,547,000USD-827,000USD-1,613,000USD-1,786,000USD1,995,000USD-292,000USD-1,111,000USD
    Total Cash From Operating Activities-3,359,000USD-362,000USD-1,880,000USD-2,101,000USD-4,103,000USD-936,000USD-2,059,000USD-2,863,000USD
    Capital Expenditures-221,000USD-348,000USD-387,000USD-207,000USD-206,000USD-567,000USD-331,000USD-115,000USD
    Free Cash Flow-3,580,000USD-710,000USD-2,267,000USD-2,308,000USD-4,309,000USD-1,503,000USD-2,390,000USD-2,978,000USD
    Investments2,062,000USD3,555,000USD1,640,000USD2,028,000USD3,824,000USD-1,414,000USD-25,759,000USD-115,000USD
    Total Cashflows From Investing Activities1,841,000USD3,207,000USD1,640,000USD2,028,000USD3,824,000USD-1,414,000USD-25,759,000USD-115,000USD
    Net Borrowings0USD0USD0USD0USD1,110,000USD0USD0USD—
    Total Cash From Financing Activities-88,000USD-137,000USD168,000USD-28,000USD-52,000USD-87,000USD15,367,000USD-22,000USD
    Change In Cash-1,606,000USD2,708,000USD-72,000USD-101,000USD-331,000USD-2,437,000USD-12,451,000USD-3,000,000USD
    Begin Period Cash Flow5,912,000USD3,204,000USD3,276,000USD3,377,000USD3,708,000USD6,145,000USD18,596,000USD21,596,000USD
    End Period Cash Flow4,306,000USD5,912,000USD3,204,000USD3,276,000USD3,377,000USD3,708,000USD6,145,000USD18,596,000USD
    Other Cashflows From Financing Activities-88,000USD-1,293,000USD-1,054,000USD-28,000USD-1,166,000USD-87,000USD226,000USD-103,000USD
    Sale Purchase Of Stock—55,000USD—56,000USD0USD—118,000USD0USD
    Issuance Of Capital Stock—0USD———0USD——
    Unclassified Financing Cash Flow—1,101,000USD1,222,000USD———15,023,000USD—
    Other Cashflows From Investing Activities—————4,000,000USD125,000USD—
    Unclassified Investing Cash Flow—————-3,433,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USD
    Net Income-17,259,000USD-26,745,000USD-36,780,000USD-47,468,000USD-9,803,000USD3,570,000USD-1,305,000USD
    Depreciation6,342,000USD6,578,000USD5,660,000USD3,165,000USD2,883,000USD2,044,000USD1,623,000USD
    Stock Based Compensation3,429,000USD3,666,000USD4,137,000USD3,711,000USD1,551,000USD300,000USD75,000USD
    Other Non Cash Items1,469,000USD5,075,000USD6,224,000USD22,456,000USD906,000USD7,000USD12,000USD
    Change To Account Receivables-374,000USD-494,000USD314,000USD380,000USD-49,000USD-2,352,000USD-104,000USD
    Change To Inventory-2,368,000USD244,000USD330,000USD-7,550,000USD-2,253,000USD-987,000USD996,000USD
    Change In Working Capital-2,679,000USD-873,000USD2,249,000USD-7,334,000USD-1,769,000USD-5,506,000USD2,299,000USD
    Total Cash From Operating Activities-8,646,000USD-12,391,000USD-18,814,000USD-27,400,000USD-9,069,000USD2,505,000USD2,172,000USD
    Capital Expenditures-1,148,000USD-1,125,000USD-7,934,000USD-28,149,000USD-19,877,000USD-5,466,000USD-2,649,000USD
    Free Cash Flow-9,794,000USD-13,516,000USD-26,748,000USD-55,549,000USD-28,946,000USD-2,961,000USD-477,000USD
    Investments11,847,000USD-27,275,000USD-12,352,000USD-28,149,000USD1,827,000USD3,704,000USD-5,568,000USD
    Total Cashflows From Investing Activities10,699,000USD-27,275,000USD-7,737,000USD-28,149,000USD-17,521,000USD-1,735,000USD-8,156,000USD
    Net Borrowings1,110,000USD0USD-10,000,000USD10,135,000USD11,889,000USD-1,599,000USD-865,000USD
    Total Cash From Financing Activities151,000USD14,890,000USD12,799,000USD10,267,000USD110,793,000USD-1,599,000USD8,570,000USD
    Sale Purchase Of Stock55,000USD135,000USD252,000USD294,000USD99,057,000USD0USD-19,468,000USD
    Issuance Of Capital Stock0USD15,104,000USD22,915,000USD0USD102,672,000USD102,672,000USD35,638,000USD
    Change In Cash2,204,000USD-24,776,000USD-13,752,000USD-45,282,000USD84,203,000USD-829,000USD2,586,000USD
    Begin Period Cash Flow3,708,000USD28,484,000USD42,236,000USD87,518,000USD3,315,000USD4,144,000USD1,558,000USD
    End Period Cash Flow5,912,000USD3,708,000USD28,484,000USD42,236,000USD87,518,000USD3,315,000USD4,144,000USD
    Other Cashflows From Financing Activities-1,170,000USD-214,000USD296,000USD-307,000USD-3,768,000USD-1,554,000USD28,885,000USD
    Other Cashflows From Investing Activities—125,000USD197,000USD—529,000USD27,000USD61,000USD
    Unclassified Financing Cash Flow—14,969,000USD22,503,000USD—3,615,000USD1,554,000USD—
    Dividends Paid——-252,000USD———-270,000USD
    Unclassified Investing Cash Flow——12,352,000USD28,149,000USD———
    Change To Liabilities———572,000USD270,000USD53,000USD3,930,000USD
    Unclassified Operating Cash Flow———-1,930,000USD-2,837,000USD2,090,000USD—
    Cash And Cash Equivalents Changes————84,203,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyInternational526,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States11,659,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductClinical Solutions2,428,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductLab Essentials9,184,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30ProductOther Product573,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyInternational516,000USD0001850902-26-000008
    Q1 2026Quarterly · 2026-03-31GeographyUnited States10,561,000USD0001850902-26-000008
    Q1 2026Quarterly · 2026-03-31ProductClinical Solutions2,145,000USD0001850902-26-000008
    Q1 2026Quarterly · 2026-03-31ProductLab Essentials8,395,000USD0001850902-26-000008
    Q1 2026Quarterly · 2026-03-31ProductOther Product537,000USD0001850902-26-000008
    Q4 2025Quarterly · 2025-12-31GeographyInternational616,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States9,368,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductClinical Solutions2,722,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductLab Essentials6,827,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductOther Product435,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyInternational2,271,000USD0001850902-26-000002
    FY 2025Yearly · 2025-12-31GeographyUnited States38,249,000USD0001850902-26-000002
    FY 2025Yearly · 2025-12-31ProductClinical Solutions7,650,000USD0001850902-26-000002
    FY 2025Yearly · 2025-12-31ProductLab Essentials31,044,000USD0001850902-26-000002
    FY 2025Yearly · 2025-12-31ProductOther Product1,826,000USD0001850902-26-000002
    Q3 2025Quarterly · 2025-09-30GeographyInternational622,000USD0001193125-25-272321
    Q3 2025Quarterly · 2025-09-30GeographyUnited States9,832,000USD0001193125-25-272321
    Q3 2025Quarterly · 2025-09-30ProductClinical Solutions1,706,000USD0001193125-25-272321
    Q3 2025Quarterly · 2025-09-30ProductLab Essentials8,308,000USD0001193125-25-272321
    Q3 2025Quarterly · 2025-09-30ProductOther Product440,000USD0001193125-25-272321
    Q2 2025Quarterly · 2025-06-30GeographyInternational510,000USD0000950170-25-105825
    Q2 2025Quarterly · 2025-06-30GeographyUnited States9,777,000USD0000950170-25-105825
    Q2 2025Quarterly · 2025-06-30ProductClinical Solutions2,060,000USD0000950170-25-105825
    Q2 2025Quarterly · 2025-06-30ProductLab Essentials7,792,000USD0000950170-25-105825
    Q2 2025Quarterly · 2025-06-30ProductOther Product435,000USD0000950170-25-105825
    Q1 2025Quarterly · 2025-03-31GeographyInternational523,000USD0001850902-26-000008
    Q1 2025Quarterly · 2025-03-31GeographyUnited States9,272,000USD0001850902-26-000008
    Q1 2025Quarterly · 2025-03-31ProductClinical Solutions1,162,000USD0001850902-26-000008
    Q1 2025Quarterly · 2025-03-31ProductLab Essentials8,117,000USD0001850902-26-000008
    Q1 2025Quarterly · 2025-03-31ProductOther Product516,000USD0001850902-26-000008
    Q4 2024Quarterly · 2024-12-31GeographyInternational501,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States8,764,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductClinical Solutions1,850,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductLab Essentials6,818,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductOther Product597,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational1,826,000USD0001850902-26-000002
    FY 2024Yearly · 2024-12-31GeographyUnited States35,919,000USD0001850902-26-000002
    FY 2024Yearly · 2024-12-31ProductClinical Solutions7,097,000USD0001850902-26-000002
    FY 2024Yearly · 2024-12-31ProductLab Essentials28,883,000USD0001850902-26-000002
    FY 2024Yearly · 2024-12-31ProductOther Product1,765,000USD0001850902-26-000002
    Q3 2024Quarterly · 2024-09-30GeographyInternational519,000USD0001193125-25-272321
    Q3 2024Quarterly · 2024-09-30GeographyUnited States9,057,000USD0001193125-25-272321
    Q3 2024Quarterly · 2024-09-30ProductClinical Solutions1,964,000USD0001193125-25-272321
    Q3 2024Quarterly · 2024-09-30ProductLab Essentials7,161,000USD0001193125-25-272321
    Q3 2024Quarterly · 2024-09-30ProductOther Product451,000USD0001193125-25-272321
    FY 2023Yearly · 2023-12-31GeographyInternational1,684,000USD0000950170-25-035705
    FY 2023Yearly · 2023-12-31GeographyUnited States35,000,000USD0000950170-25-035705
    FY 2023Yearly · 2023-12-31ProductClinical Solutions6,738,000USD0000950170-25-035705
    FY 2023Yearly · 2023-12-31ProductLab Essentials28,800,000USD0000950170-25-035705
    FY 2023Yearly · 2023-12-31ProductOther Product1,146,000USD0000950170-25-035705
    FY 2022Yearly · 2022-12-31GeographyInternational1,317,000USD0000950170-24-036624
    FY 2022Yearly · 2022-12-31GeographyUnited States40,103,000USD0000950170-24-036624
    FY 2022Yearly · 2022-12-31ProductClinical Solutions8,445,000USD0000950170-23-010926
    FY 2022Yearly · 2022-12-31ProductLab Essentials31,772,000USD0000950170-23-010926
    FY 2022Yearly · 2022-12-31ProductOther Product1,197,000USD0000950170-23-010926
    FY 2022Yearly · 2022-12-31ProductSample Transport6,000USD0000950170-23-010926
    FY 2021Yearly · 2021-12-31GeographyInternational1,085,000USD0000950170-23-010926
    FY 2021Yearly · 2021-12-31GeographyUnited States35,808,000USD0000950170-23-010926
    FY 2021Yearly · 2021-12-31ProductClinical Solutions6,793,000USD0000950170-23-010926
    FY 2021Yearly · 2021-12-31ProductLab Essentials27,184,000USD0000950170-23-010926
    FY 2021Yearly · 2021-12-31ProductOther Product1,386,000USD0000950170-23-010926
    FY 2021Yearly · 2021-12-31ProductSample Transport1,530,000USD0000950170-23-010926
    FY 2020Yearly · 2020-12-31GeographyInternational1,159,000USD0000950170-22-004176
    FY 2020Yearly · 2020-12-31GeographyUnited States30,138,000USD0000950170-22-004176
    FY 2020Yearly · 2020-12-31ProductClinical Solutions4,807,000USD0000950170-22-004176
    FY 2020Yearly · 2020-12-31ProductLab Essentials21,240,000USD0000950170-22-004176
    FY 2020Yearly · 2020-12-31ProductOther Product953,000USD0000950170-22-004176
    FY 2020Yearly · 2020-12-31ProductSample Transport4,297,000USD0000950170-22-004176

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.